999 resultados para Éthique clinique
Resumo:
La loi sur la procréation médicalement assistée (LPMA) est entrée en vigueur en Suisse en 2001. La PMA est subordonnée au bien de l'enfant, et seul un couple marié peut recourir au don de sperme. Concernant l'insémination artificielle avec sperme de donneur (IAD), la loi a prévu que l'enfant âgé de 18 ans révolu peut obtenir des données concernant l'identité du donneur, et même, en cas d'intérêt légitime, il a le droit d'obtenir toutes les données relatives au donneur. Il est précisé également qu'une assistance psychologique doit être offerte aux couples avant, pendant et après un traitement. L'Unité de médecine de la reproduction (UMR) et le Centre de procréation médicalement assistée (CPMA) à Lausanne ont développé depuis une douzaine d'années une assistance psychologique ajustée à chaque couple appelée « bilan des ressources ». Dans le cas des demandes d'IAD, des questions spécifiques sont discutées, entre autres: faut-il parler à son entourage, à l'enfant de l'origine de sa conception, comment et quand en parler ? Ces questions peuvent aussi être abordées dans des groupes de couples concernés par le sujet de manière fructueuse. Notre expérience nous montre que ces entretiens psychologiques systématiques aident les couples à cheminer tranquillement dans leur réflexion sur le thème du secret, de l'attachement, du droit de l'enfant à savoir d'où il vient.
Resumo:
Bronchoalveolar lavage (BAL) is a minimally invasive procedure used to characterize the status of the alveolar space. Standardization of the procedure and the analysis of samples taken is essential for their proper interpretation. In nonresolving or ventilator-associated pneumonia, BAL contributes to the detection of resistant pathogens and noninfectious etiologies. In immunocompromised hosts with radiological infiltrates, BAL should be performed early during work-up since outcome is significantly modified in this population group. In cases of interstitial lung disease, BAL can exclude infectious or neoplastic causes. Associated with a clinical and radiological evaluation, it provides valuables additional diagnostic information.
Resumo:
The clinicopathologic case of a 53-year-old female patient with an abnormal tumor growing on the mucous part of the superior right eyelid is reported. The patient was operated on for ten years ago and a whitish mass slowly developed on the conjunctival face of the eyelid disturbing the use of corneal lenses. It was hard, painless and had the shape of a flat mushroom. The removal was performed under local anesthesia and allowed us to resect a hard and fibrous lesion. Histopathology showed that the lesion was made of a fibrous tissue organized like a hypertrophic scar. Surgical treatment of chalazion is frequent and rarely gives rise to abnormal scarring.
Resumo:
Toxoplasmosis is an infectious disease caused by the intracellular parasite Toxoplasma gondii. In Switzerland about a third of the population has antibodies against this pathogen and has thus already been in contact with the parasite or has contracted the disease. Immunocompetent patients are usually asymptomatic (80-90%) during primary infection. The most common symptom is neck or occipital lymphadenopathy. Serology is the diagnostic gold standard in immunocompetent individuals. The presence of IgM antibodies is however not sufficient to make a definite diagnosis of acute toxoplasmosis. Distinction between acute and chronic toxoplasmosis requires additional serological tests (IgG avidity test). If required, the most used and probably most effective treatment is the combination of pyrimethamine and sulfadiazine, with folinic acid.
Resumo:
How to summarize and facilitate the implementation of national and international guidelines in clinical practice? To adress these issues, we present a summary of dyslipidemia management for general practitioners. To achieve these aims, we adopted strategies based on international and national guidelines and focused on clinical applications which implies to choose specific options, such as the use of cardiovascular risk score and specific therapies as first options.